XML 68 R62.htm IDEA: XBRL DOCUMENT
v3.25.3

Commitments and Contingencies - Contingencies - Additional Information (Detail) € in Millions |  |  |  |  | 1 Months Ended | 12 Months Ended |  |  |  |  |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Oct. 10, 2024 USD ($) | Jun. 14, 2024 USD ($) | Nov. 09, 2022 USD ($) | Jun. 02, 2022 USD ($) | Sep. 30, 2024 USD ($) | Jun. 30, 2023 USD ($) | Nov. 30, 2022 USD ($) | Feb. 28, 2021 USD ($) | Jul. 31, 2014 USD ($) | Sep. 30, 2013 USD ($) | Apr. 30, 2013 USD ($) | Dec. 31, 2011 USD ($) | Dec. 31, 2023 USD ($) | Sep. 30, 2025 USD ($) | Jan. 31, 2025 EUR (€) | Dec. 31, 2024 USD ($) | Mar. 28, 2024 USD ($) | Aug. 21, 2023 USD ($) | Jul. 08, 2021 USD ($) | Mar. 31, 2021 EUR (€) | Nov. 30, 2020 EUR (€) | Feb. 29, 2012 USD ($) | Jul. 31, 2008 USD ($)
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales of Effexor |  |  |  |  |  |  |  |  |  |  |  | $ 2,600,000,000 |  |  |  |  |  |  |  |  |  |  |
Annual sales of Lamictal |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 950,000,000 | $ 2,300,000,000
Annual sales of Niaspan |  |  |  |  |  |  |  |  |  | $ 1,100,000,000 | $ 416,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Annual Sales Of Xifaxan |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,500,000,000 |  |  |  |  |  |  |  |  |
Litigation settlement amount |  |  |  |  |  | $ 4,250,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement amount awarded distribution period |  |  |  |  |  | 13 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Generic modafinil, and imposed fines amount |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,668,000,000 |  | $ 4,881,000,000 |  |  |  |  | € 60.5 |  |
Loss Contingency Accrual, Provision |  |  |  |  |  |  |  |  | $ 235,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales of the time of settlement of viread |  |  |  |  |  |  |  | $ 582,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales of the time of settlement of Truvada |  |  |  |  |  |  |  | 2,400,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales of the time of settlement of Atripla |  |  |  |  |  |  |  | 2,900,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales of the time of New launch of viread |  |  |  |  |  |  |  | 728,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales of the time of New launch of Truvada |  |  |  |  |  |  |  | 2,100,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales of the time of New launch of Atripla |  |  |  |  |  |  |  | $ 444,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation Settlement Amount Distributable In Kind |  |  |  |  |  | $ 1,200,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrual for Environmental Loss Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 300,000 |  |  |  |  |  |  |
Loss Contingencies On Environmental Laws Penalty |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,400,000 |  |  |  |
Commission surety underwritten guarantees | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 462.6 |  |  |  |  |  |  |  |
Litigation fine amount of copaxone | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 462.6 |  |  |
Litigation Settlement amount payable year one |  |  |  |  | $ 35,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement amount payable remainder of fiscal year |  |  |  |  | 80,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other commitment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 150,000,000 |  |  |  |  |  |
Annual Sales Of Revlimid |  |  |  |  |  |  | $ 3,500,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual Sales At The Time Of Nuvigil Entered Into First Settlement Of With AN ANDA Filer |  | $ 300,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingency Claims Dismissed Value Paid To Each State Proportional To Its Share Of National Population |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,000,000,000,000 |  |  |  |  |  |  |  |  |  |
Percentage Of Share Of The National Population |  |  |  |  |  |  |  |  |  |  |  |  | 1.00% |  |  |  |  |  |  |  |  |  |
Percentgae of amount in cash settlement |  |  |  |  |  | 20.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation Settlement Amount Distributable in cash |  |  |  |  |  | $ 240,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingency, Damages Awarded, Value |  |  | $ 176,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Prosecution Agreement With U.S. Department of Justice [Member] | Donation of Clotrimazole and Tobramycin [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other commitment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 50,000,000 |  |  |  |  |
Deferred Prosecution Agreement With U.S. Department of Justice [Member] | Fine for Violating the Antitrust Laws [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other commitment, to be paid, year five |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 135,000,000 |  |  |  |  |
Other commitment to pay for each year |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 22,500,000 |  |  |  |  |
Other commitment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 225,000,000 |  |  |  |  |
Opioid Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency aggregate payments paid |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 412,000,000 |  |  |  |  |  |  |  |  |
Loss contingency accrual, product liability, undiscounted, to be paid, year five |  |  |  |  |  | 339,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency accrual, product liability, undiscounted, to be paid, year four |  |  |  |  |  | 385,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency accrual, product liability, undiscounted, to be paid, year three |  |  |  |  |  | 364,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency accrual, product liability, undiscounted, to be paid, year two |  |  |  |  |  | 363,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency accrual, product liability, undiscounted, to be paid, year one |  |  |  |  |  | $ 419,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Modafinil Settlement Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Settlement as a percentage of aggregate subdivisions and tribes |  |  |  |  |  | 100.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Civil Action In Respect Of Donations To Patient Assistance Programmers [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Generic modafinil, and imposed fines amount | $ 425,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency accrual due in fifth year | 175,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency accrual due in fourth year | 99,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency accrual due in third year | 49,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency accrual next twelve months | 34,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency accrual remainder of fiscal year | 19,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Civil Investigative Demand From Department Of Justice Civil Division [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingency Accrual, Provision | 25,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Civil Investigative Demand From Department Of Justice Civil Division [Member] | Two Thousand And Twenty Five [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency accrual current | 15,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Civil Investigative Demand From Department Of Justice Civil Division [Member] | Two Thousand And Twenty Four [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency accrual current | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ontario Teachers Securities Litigation [Member] | Settled Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement amount |  |  |  | $ 420,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation With US Hospitals And Other Healthcare Providers [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement amount |  |  |  |  | $ 126,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement amount awarded distribution period |  |  |  |  | 18 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product WAC Value |  |  |  |  | $ 49,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product WAC Term |  |  |  |  | 7 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Annual sales at The time of nuvigil entered into first settlement of with AN ANDA hiler. + References No definition available. + Details
Name: | teva_AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Annual sales of effexor. + References No definition available. + Details
Name: | teva_AnnualSalesOfEffexor
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Annual sales of Lamictal. + References No definition available. + Details
Name: | teva_AnnualSalesOfLamictal
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Annual sales of Niaspan. + References No definition available. + Details
Name: | teva_AnnualSalesOfNiaspan
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Annual sales of revlimid. + References No definition available. + Details
Name: | teva_AnnualSalesOfRevlimid
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Annual sales of the time of new launch of Atripla. + References No definition available. + Details
Name: | teva_AnnualSalesOfTheTimeOfNewLaunchOfAtripla
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Annual sales of the time of New launch of truvada. + References No definition available. + Details
Name: | teva_AnnualSalesOfTheTimeOfNewLaunchOfTruvada
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Annual sales of the time of new launch of viread. + References No definition available. + Details
Name: | teva_AnnualSalesOfTheTimeOfNewLaunchOfViread
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Annual sales of the time of settlement of atripla. + References No definition available. + Details
Name: | teva_AnnualSalesOfTheTimeOfSettlementOfAtripla
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Annual sales of the time of settlement of truvada. + References No definition available. + Details
Name: | teva_AnnualSalesOfTheTimeOfSettlementOfTruvada
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Annual sales of the time of settlement of viread. + References No definition available. + Details
Name: | teva_AnnualSalesOfTheTimeOfSettlementOfViread
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Annual sales of Xifaxan. + References No definition available. + Details
Name: | teva_AnnualSalesOfXifaxan
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Commission surety underwritten guarantees. + References No definition available. + Details
Name: | teva_CommissionSuretyUnderwrittenGuarantees
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Commitment And Contingencies [Line Items] + References No definition available. + Details
Name: | teva_CommitmentAndContingenciesLineItems
Namespace Prefix: | teva_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Litigation fine amount of copaxone. + References No definition available. + Details
Name: | teva_LitigationFineAmountOfCopaxone
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Litigation settlement amount awarded distribution period. + References No definition available. + Details
Name: | teva_LitigationSettlementAmountAwardedDistributionPeriod
Namespace Prefix: | teva_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Litigation settlement amount distributable in cash. + References No definition available. + Details
Name: | teva_LitigationSettlementAmountDistributableInCash
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Litigation settlement amount distributableIn kind. + References No definition available. + Details
Name: | teva_LitigationSettlementAmountDistributableinKind
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Litigation settlement amount payable in cash percentage + References No definition available. + Details
Name: | teva_LitigationSettlementAmountPayableInCashPercentage
Namespace Prefix: | teva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Litigation settlement amount payable remainder of fiscal year. + References No definition available. + Details
Name: | teva_LitigationSettlementAmountPayableRemainderOfFiscalYear
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Litigation settlement amount payable year one. + References No definition available. + Details
Name: | teva_LitigationSettlementAmountPayableYearOne
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Loss contingencies on environmental laws penalty. + References No definition available. + Details
Name: | teva_LossContingenciesOnEnvironmentalLawsPenalty
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Loss contingency accrual due in fifth year. + References No definition available. + Details
Name: | teva_LossContingencyAccrualDueInFifthYear
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Loss contingency accrual due in fourth year. + References No definition available. + Details
Name: | teva_LossContingencyAccrualDueInFourthYear
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Loss contingency accrual due in year three. + References No definition available. + Details
Name: | teva_LossContingencyAccrualDueInYearThree
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Loss contingency accrual next twelve months. + References No definition available. + Details
Name: | teva_LossContingencyAccrualNextTwelveMonths
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Loss contingency accrual remainder of fiscal year. + References No definition available. + Details
Name: | teva_LossContingencyAccrualRemainderOfFiscalYear
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Loss contingency aggregate payments paid. + References No definition available. + Details
Name: | teva_LossContingencyAggregatePaymentsPaid
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Loss contingency claims dismissed value paid to each state proportional to its share of national population + References No definition available. + Details
Name: | teva_LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Other commitment to pay for each year. + References No definition available. + Details
Name: | teva_OtherCommitmentToPayForEachYear
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Percentage of share of the national population. + References No definition available. + Details
Name: | teva_PercentageOfShareOfTheNationalPopulation
Namespace Prefix: | teva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Product weighted average cost. + References No definition available. + Details
Name: | teva_ProductWeightedAverageCost
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Product weighted average cost term. + References No definition available. + Details
Name: | teva_ProductWeightedAverageCostTerm
Namespace Prefix: | teva_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Settlement as a percentage of aggregate subdivisions and tribes. + References No definition available. + Details
Name: | teva_SettlementAsAPercentageOfAggregateSubdivisionsAndTribes
Namespace Prefix: | teva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Total costs accrued as of the balance sheet date for environmental loss contingencies. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 410 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481931/410-30-50-10 Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 410 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481931/410-30-50-10 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 410 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481899/410-30-55-16 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.Y.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1 Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 410 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481931/410-30-50-7 + Details
Name: | us-gaap_AccrualForEnvironmentalLossContingencies
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount awarded to other party in judgment or settlement of litigation. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementAmountAwardedToOtherParty
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of loss contingency liability. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10 + Details
Name: | us-gaap_LossContingencyAccrualAtCarryingValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details
Name: | us-gaap_LossContingencyAccrualCarryingValueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Undiscounted amount of accrual for damage arising from third-party use of product or process to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.Y.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1 + Details
Name: | us-gaap_LossContingencyAccrualProductLiabilityUndiscountedDueInFifthYear
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Undiscounted amount of accrual for damage arising from third-party use of product or process to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.Y.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1 + Details
Name: | us-gaap_LossContingencyAccrualProductLiabilityUndiscountedDueInFourthYear
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Undiscounted amount of accrual for damage arising from third-party use of product or process to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.Y.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1 + Details
Name: | us-gaap_LossContingencyAccrualProductLiabilityUndiscountedDueInSecondYear
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Undiscounted amount of accrual for damage arising from third-party use of product or process to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.Y.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1 + Details
Name: | us-gaap_LossContingencyAccrualProductLiabilityUndiscountedDueInThirdYear
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Undiscounted amount of accrual for damage arising from third-party use of product or process to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.Y.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1 + Details
Name: | us-gaap_LossContingencyAccrualProductLiabilityUndiscountedDueWithinOneYear
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details
Name: | us-gaap_LossContingencyAccrualProvision
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of damages awarded to the plaintiff in the legal matter. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details
Name: | us-gaap_LossContingencyDamagesAwardedValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details
Name: | us-gaap_OtherCommitment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of commitment classified as other to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details
Name: | us-gaap_OtherCommitmentDueInFifthYear
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | teva_AgreementAxis=teva_DeferredProsecutionAgreementWithU.s.DepartmentOfJusticeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=teva_DonationOfClotrimazoleAndTobramycinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=teva_FineForViolatingTheAntitrustLawsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=teva_OpioidLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=teva_ModafinilSettlementAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=teva_CivilActionInRespectOfDonationsToPatientAssistanceProgrammersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=teva_CivilInvestigativeDemandFromDepartmentOfJusticeCivilDivisionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | teva_PeriodAxis=teva_TwoThousandAndTwentyFiveMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | teva_PeriodAxis=teva_TwoThousandAndTwentyFourMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=teva_OntarioTeachersSecuritiesLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=teva_LitigationWithUsHospitalsAndOtherHealthcareProvidersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |